Case Report

Serratia marcescens Endocarditis with Perivalvular Abscess Presenting as Atrioventricular Block

Aaron Richardson,1 Andres Martinez,2 Shreya Ghetiya,3 Emil Missov,1 Robert Percy,1 and Srinivasan Sattiraju1

1Division of Cardiology, University of Florida College of Medicine Jacksonville, Jacksonville, FL, USA
2Department of Medicine, University of Florida College of Medicine Jacksonville, Jacksonville, FL, USA

Correspondence should be addressed to Aaron Richardson; aaron.richardson@jax.ufl.edu

Received 1 February 2020; Accepted 27 May 2020; Published 11 June 2020

1.Introduction

Serratia marcescens is an aerobic, motile, oxidase-negative, and Gram-negative bacillus first identified in 1819 [1]. S. marcescens is an opportunistic pathogen associated with intravenous drug use, immunosuppression, previous antibiotic exposure, and indwelling catheterization. S. marcescens has a number of factors increasing virulence including fimbria-like adhesions, which allow for surface attachment and subsequent formation of biofilms increasing the likelihood of infection to humans. S. marcescens is most commonly known to cause urinary tract infections, pneumonia, and soft tissue infections. Infective endocarditis by S. marcescens, first described in 1951, is extremely rare accounting for only 0.14% of all cases of endocarditis [2–4].

2. Case Report

A 33-year-old male with a past medical history of Hodgkin lymphoma, nonischemic cardiomyopathy ejection fraction of 25–30%, severe aortic stenosis, hepatitis C, and active intravenous (IV) drug abuse was admitted to the hospital following a motor vehicle accident. Upon admission, he was found to have a closed severely displaced zone III sacral fracture for which conservative management was pursued due to patient’s comorbidities.

Approximately 3 days into the admission, he required emergent placement of a temporary pacing wire. Tranesophageal echocardiogram was ordered and revealed an aortic root abscess. Given the comorbidities and active IV drug use, conservative management was pursued. Although rare, trends suggest that this pathogen may be on the rise. Further research is needed to better understand how to effectively manage this pathogen.
piperacillin/tazobactam for the *Serratia marcescens* urinary tract infection.

Around 10 days after the patient's diagnosis of *S. marcescens* urinary tract infection, he developed a 39.5 degree Celsius fever, which prompted collection of additional blood cultures. These cultures were positive (2 out of 2) for *S. marcescens*, same phenotype as previous urine cultures, sensitive to gentamycin, levofloxacin, and trimethoprim/sulfamethoxazole. He was treated with intravenous cefepime. One week after diagnosis of bacteremia, cardiology was consulted for bradycardia. Upon cardiology review of the initial electrocardiogram (ECG), it was found the patient had a Mobitz type 1 block (Figure 1). Patient was examined bedside and found to be asymptomatic and hemodynamically stable. A follow-up ECG was ordered the next day, which showed the patient had progressed to a complete AV block (Figure 2). Patient was hemodynamically stable when this ECG was obtained, and electrophysiology consultation was recommended. However, before the patient could be evaluated by electrophysiology, the patient had 2 symptomatic episodes of torsade de pointes. The patient was given intravenous magnesium with methadone discontinued. Given the instability of the patient, it was decided to emergently take the patient to the electrophysiology lab and place a temporary pacing wire with an external generator. Once this was completed, a transesophageal echocardiogram was ordered for evaluation of endocarditis. Transesophageal echocardiogram revealed an aortic valve area of 0.9 cm² in addition to an echogenic density around the aortic root that extended into the interatrial septum. A small echolucent area was noted within this density. A small mobile echogenic density was also seen attached to the base of aortic leaflets (Figures 3–6). These
findings in addition to the complete AV block and bacteremia were all consistent with an aortic root abscess. Cardiothoracic surgery was consulted; however, given patient’s multiple comorbidities, conservative treatment was pursued. The patient was successfully treated with 6 weeks of intravenous cefepime in combination with 4 weeks of ciprofloxacin. Once cefepime was completed, the patient was then placed on oral antibiotic indefinitely until a possible future surgical intervention could take place.

3. Discussion

Endocarditis due to *S. marcescens* is indistinguishable clinically from other causes of endocarditis. Although most intravenous drug users with endocarditis have right-side involvement of the heart, *S. marcescens* has predilection for left-sided valves. *S. marcescens* endocarditis is difficult to treat due to resistance to many antibiotics including 1st and 2nd generation cephalosporins and penicillins. *S. marcescens*
has been shown to be susceptible to 3rd and 4th generation cephalosporins, monobactams, carbapenems, fluoroquinolones, and aminoglycosides. Resistance to antibiotics is obtained through high-level production of chromosomal AmpC cephalosporinases combined with decreased outer membrane permeability along with the synthesis of β-lactamases [2, 4].

*S. marcescens* is associated with high morbidity. Paravalvular complications and valvular destruction are documented in previous cases of *S. marcescens* endocarditis. Surgical intervention is recommended within 7–10 days, especially for patients with left side involvement [1]. In fact, mortality is noted to be as high as 85% in patients with *S. marcescens* endocarditis who only received medical therapy.
Treatment with only medical therapy has been more successful in those diagnosed with right-side endocarditis [3].

The 2005 Infectious Diseases Society of America (IDSA) and 2009 European Society of Cardiology make no specific recommendations on antimicrobial therapy but suggest the use of a combination of a beta-lactam and an aminoglycoside for at least 6 weeks of treatment. The most important step in treatment is to obtain cultures with sensitivities in order to appropriately focus treatment. Surgical consultation must be obtained if vegetations, paravalvular abscess, or involvement of valves are noted on echocardiogram. Failure to seek appropriate surgical treatment can result in persistent bacteremia, risk of embolization, and heart failure [1, 5].

4. Conclusion

*S. marcescens* endocarditis is rare, but trends suggest that this pathogen may be on the rise. This case presents the importance of early identification, culturing, and identification of antibiotic sensitivity given the resistance of this pathogen to antibiotics. No clear guidelines exist for treatment of *S. marcescens* given its rarity. Once diagnosed, early surgical consultation should be considered. Further research is needed to understand how to manage this pathogen.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest to disclose.

**References**

[1] H.-M. Yeung, B. Chavarria, and D. Shamsavari, “A complicated case of *Serratia marcescens* infective endocarditis in the era of the current opioid epidemic,” *Case Reports in Infectious Diseases*, vol. 2018, Article ID 5903589, 5 pages, 2018.

[2] V. K. Phadke and J. T. Jacob, "Marvelous but morbid: infective endocarditis due to *Serratia marcescens*," *Infectious Diseases in Clinical Practice*, vol. 24, no. 3, pp. 143–150, 2016.

[3] Y. Hadano, T. Kamiya, and N. Uenishi, “A fatal case of infective endocarditis caused by an unusual suspect: *Serratia marcescens*,” *Internal Medicine*, vol. 51, no. 11, pp. 1425–1428, 2012.

[4] A. Nikolakopoulos, N. Koutsogiannis, P. Xaplanteri, C. Gogos, F. Kolonitsiou, and A. Lekkou, "A case of *Serratia marcescens* endocarditis in a nonintravenous drug-using male patient and review of literature," *Case Reports in Infectious Diseases*, vol. 2019, Article ID 3715404, 4 pages, 2019.

[5] L. M. Baddour, W. R. Wilson, A. S. Bayer et al., "Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications," *Circulation*, vol. 132, no. 15, pp. 1435–1486, 2015.